the updates below are just from this year thru march (I think at least one update is missing)
all the work they were doing before their entry into the covid sweepstakes is STILL to our knowledge being done.
apparently the govt contractor inquiry prompted Bret to do some experimenting in ca late March
(after the 3-16 update bc prior to that NNLX was not entering into the covid melee because of NNLX's experience w ebola- they couldnt stir any interest in their n-assay re ebola - so originally they were just going to bypass covid 19 - remember that nobody in the usa knew much about covid prior to march)
well, NNLX IS in the covid sweepstakes!!! - the work being conducted by their 2 NDA partners is necessary for the FDA EUA. Did ppl think different???
Once they have the EUA the sky is the limit -given problems/limitations w current testing methods-as explained by machs and mits-and any limitations re finances
what else do ppl expect NNLX to be doing???
If ppl have answers NNLX does not have please forward those answers to NNLX- or forbid -even us dumb hillbilly folk so we can be educated real proper like.
The same ppl who were bashing the ceo were praising him a while back and now are bashing him again - why?
At least explain what he should 've done that causes such an about face - I have the same face everyday.
any startup -and no matter how long a co has been in existence it can be said to be a startup until revenue approaches expenses- has a varied minefield to navigate -its not easy in the real world. If it was easy in the real world then over 90% of startups would not fail. Biotechs and mining are said to be the most difficult startups.
the roadblocks have been explained all along.
But why do some seem to think NNLX is in a worse position than before they entered the covid sweepstakes????? when everything they did prior to the sweepstakes is still continuing!!!???!!! to our knowledge.
6 months ago 3-16 prior to the contractor inquiry NNLX had no intention of entering the covid race and now they could be a few weeks away from submitting their partners test results to the fda for an eua while the patent is finalized about the same time.
What's wrong with that?? What's missing other than internal finances and the limitations of their classification. If the california co is the same one NNLX associated with recently that would speed up the business processes and their gearing up for the covid testing.
I am not generally referring to sierra but mach has explained the situation re patents.
No guarantees in this world other than death and taxes so they say, but we have no reason to believe bk is in the near term cards.
Maybe I should repeat a fact-most pioneers are not even recognized except posthumously, for reasons that can be surmised/deduced.
In the scientific field some like Einstein get lucky in being recognized without a contract on his life but there are no guarantees. The world does not worship merit or intelligence/ foresight -it worships money at any dishonest price or manipulation. If honest ppl can break through those manipulations its often unusual.
So the problem is how do you partner with those who can play the manipulation game without being destroyed-its an age old game. The rarity of that partnership explains why the world is in the condition it is in and why those with answers are not only usually not listened to but rather have to run a gauntlet in the same metaphorical manner as the Clint Eastwood movie of the same name.
Posted On: 03/16/2020 2:24:17 AM
Posted By: Kachingpdx1
https://www.youtube.com/watch?v=zMRrNY0pxfM
NanoLogix Update - COVID-19 Detection
Last week the Company was contacted by a respected U.S. Government Contractor regarding our N-Assay Technology and its potential Coronavirus (COVID-19) testing capabilities.
We were informed by the contractor that they will bear all costs of configuration and testing of the N-Assay at their facilities. Following the conversation, NanoLogix sent a letter agreeing in principle to the proposal, which was rapidly acknowledged, and is awaiting a formal agreement from the contractor.
NanoLogix will not be supplying any materials or personnel for this process and our sole participation is on an Intellectual Property (Patent) basis, stemming from the N-Assay patent issued in 2015.
We will not be involved in the potential production of test kits if the contractor determines from the testing that N-Assay kits should be used in the fight against this Coronavirus. Should that happen, it would be done by a recognized producer under license.
We are hopeful that the N-Assay and one additional Point-of Care test we are developing will be useful tools for rapid detection of any pathogens that are threats to health.
A recap of our late-February Update:
While we believe our technology could be used to develop a rapid test for the Coronavirus, based upon preliminary development work done for detection of proteins associated with Ebola in 2014 and 2015, with <3.5 hours results, we do not have the resources to independently pursue development of a Coronavirus rapid test.
The Coronavirus may be a short-lived phenomenon that is no longer an issue within a few months; there are other tests that exist that may deliver reliable results in a few hours or days, and while an N-Assay test could potentially deliver results in minutes, it may not be viewed as worthwhile in a cost/benefit analysis by various agencies or institutions.
In conclusion, we are fully committed to our current work producing filled Petri plates and development work on Urinary Tract and Yeast Infection rapid detection development utilizing a unique screening test and our N-Assay modified ELISA process.
Posted On: 02/28/2020 11:32:38 AM
Posted By: mitstevfel
Response to Coronavirus Queries both International and US
The Company continues to receive calls inquiring about Coronavirus (COVID-19) testing capabilities.
While we believe our technology could be used to develop a rapid test for the Coronavirus, based upon preliminary development work done for detection of proteins associated with Ebola in 2014, we do not have the resources to pursue development of a Coronavirus rapid test. There are a small number of BioSafety Level 4 labs in the US (4+/-) where development work on dangerous viruses can be done and their calendars are booked months to years in advance with daily costs that can run into tens of thousands of dollars. The Coronavirus may be a short-lived phenomenon that is no longer an issue within a few months; there are other tests that exist that may deliver reliable results in a few hours or a day, and while a test we develop may potentially deliver results in minutes, it may not be viewed as worthwhile in a cost:benefit analysis by various agencies or institutions.
In conclusion, we are fully committed to our current work on Urinary Tract and Yeast Infections rapid detection development utilizing a unique screening test and our N-Assay modified ELISA process.
Posted On: 01/31/2020 3:04:22 PM
Posted By: Eudius
Update:
NanoLogix Incorporated
Response to Coronavirus Questions From Shareholders
Given a number of queries from shareholders asking if our technology could be used for rapid detection of the current Coronavirus originating in Wuhan, China we felt the following response is necessary:
Based upon positive preliminary research performed in 2014 with the N-Assay on Ebola virus protein markers, we believe both the N-Assay and the new Screening test currently under development have the potential for use in rapid detection of the Coronavirus. That said, given our focus on refinement of both the Screening Test and N-Assay Rapid Diagnostic for Urinary Tract and other bacterial and yeast infections, our limited resources as a small biotechnology company, along with the demonstrated historical lack of interest from potential partners and funders during the Ebola outbreak, we currently have no intention of individually pursuing development for Coronavirus detection without the assistance and cooperation of well-funded entities.
Posted On: 01/14/2020 11:21:31 AM
Posted By: Eudius
NanoLogix PreTest Development Update
NanoLogix is pleased to provide an additional update on the
Screening/Pretest and its potential as a standalone test
An important aspect of the Bacteria and Yeast pretest revealed during Phase One development is the ability to detect and specifically identify Candida yeast infection in human fluids, with no cross-reactivity from other microorganisms. The importance of this is three-fold. The first aspect is that this Candida test is a FIVE-MINUTE TEST. The second is that it can be offered for consumer use in retail outlets, in addition to being used by clinicians for laboratories and medical offices. The third is that there is no other consumer test that specifically identifies Candida, and in doing so, we believe it will provide the ability for consumers to self-diagnose and treat a condition that affects a large percentage of the public.
The previous update from December is provided below for reference
The first phase of Proof of Concept/Principle development work in the UK by a company with Global operations began on October 1st and was completed the first week of December at a cost of roughly $100,000. This phase demonstrated very positive results for Point of Care screening for one specific Candida strain and to very promising results for two bacteria that constitute the primary threats present in Urinary Tract Infections (UTI).
This was a necessary first of four phases that will carry through to patient studies in Houston planned for 2020. The next phase of development will begin in March, after the manufacture and delivery of custom antibodies for the remaining bacteria and Candida.
This schedule will lead to marketing of both the N-Assay and its associated screening pretest for UTI projected for 2021.
The development work on a screening/pretest for seven bacteria and two strains of Candida, though initially focussed upon UTI, will enable NanoLogix to configure the test in a multitude of ways. In doing so, we will have the capability to rapidly and accurately test for possibly up to 15-20 different types of infections, with the ability to determine the specific bacterial cause, the severity of the infection, and the bacteria antibiotic resistance. We anticipate the tests will provide Point of Care and Clinical personnel the ability to dramatically increase both accuracy and speed of diagnosis and in doing so will provide a new weapon in the battle against the development of antibiotic resistance.
The purpose of the Pretest use with the N-Assay is to have a Pretest that will indicate the presence of a specific bacteria within minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.
In our effort to secure additional funding to reach our goal of $3 million for development, expansion and marketing, we have been in contact with a number of non-NanoLogix-affiliated MDs who have expressed interest in the technology development. Those efforts will continue until we reach our funding requirements.
A PowerPoint presentation on the N-Assay Bacteria Diagnostic is included to illustrate just some of the advantages of the technology. The PowerPoint includes information on upper respiratory infections (URI), general sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.
Read More: https://investorshangout.com/Nanologix-Inc-NN...z6YBK76ng8
all the work they were doing before their entry into the covid sweepstakes is STILL to our knowledge being done.
apparently the govt contractor inquiry prompted Bret to do some experimenting in ca late March
(after the 3-16 update bc prior to that NNLX was not entering into the covid melee because of NNLX's experience w ebola- they couldnt stir any interest in their n-assay re ebola - so originally they were just going to bypass covid 19 - remember that nobody in the usa knew much about covid prior to march)
well, NNLX IS in the covid sweepstakes!!! - the work being conducted by their 2 NDA partners is necessary for the FDA EUA. Did ppl think different???
Once they have the EUA the sky is the limit -given problems/limitations w current testing methods-as explained by machs and mits-and any limitations re finances
what else do ppl expect NNLX to be doing???
If ppl have answers NNLX does not have please forward those answers to NNLX- or forbid -even us dumb hillbilly folk so we can be educated real proper like.
The same ppl who were bashing the ceo were praising him a while back and now are bashing him again - why?
At least explain what he should 've done that causes such an about face - I have the same face everyday.
any startup -and no matter how long a co has been in existence it can be said to be a startup until revenue approaches expenses- has a varied minefield to navigate -its not easy in the real world. If it was easy in the real world then over 90% of startups would not fail. Biotechs and mining are said to be the most difficult startups.
the roadblocks have been explained all along.
But why do some seem to think NNLX is in a worse position than before they entered the covid sweepstakes????? when everything they did prior to the sweepstakes is still continuing!!!???!!! to our knowledge.
6 months ago 3-16 prior to the contractor inquiry NNLX had no intention of entering the covid race and now they could be a few weeks away from submitting their partners test results to the fda for an eua while the patent is finalized about the same time.
What's wrong with that?? What's missing other than internal finances and the limitations of their classification. If the california co is the same one NNLX associated with recently that would speed up the business processes and their gearing up for the covid testing.
I am not generally referring to sierra but mach has explained the situation re patents.
No guarantees in this world other than death and taxes so they say, but we have no reason to believe bk is in the near term cards.
Maybe I should repeat a fact-most pioneers are not even recognized except posthumously, for reasons that can be surmised/deduced.
In the scientific field some like Einstein get lucky in being recognized without a contract on his life but there are no guarantees. The world does not worship merit or intelligence/ foresight -it worships money at any dishonest price or manipulation. If honest ppl can break through those manipulations its often unusual.
So the problem is how do you partner with those who can play the manipulation game without being destroyed-its an age old game. The rarity of that partnership explains why the world is in the condition it is in and why those with answers are not only usually not listened to but rather have to run a gauntlet in the same metaphorical manner as the Clint Eastwood movie of the same name.
Posted On: 03/16/2020 2:24:17 AM
Posted By: Kachingpdx1
https://www.youtube.com/watch?v=zMRrNY0pxfM
NanoLogix Update - COVID-19 Detection
Last week the Company was contacted by a respected U.S. Government Contractor regarding our N-Assay Technology and its potential Coronavirus (COVID-19) testing capabilities.
We were informed by the contractor that they will bear all costs of configuration and testing of the N-Assay at their facilities. Following the conversation, NanoLogix sent a letter agreeing in principle to the proposal, which was rapidly acknowledged, and is awaiting a formal agreement from the contractor.
NanoLogix will not be supplying any materials or personnel for this process and our sole participation is on an Intellectual Property (Patent) basis, stemming from the N-Assay patent issued in 2015.
We will not be involved in the potential production of test kits if the contractor determines from the testing that N-Assay kits should be used in the fight against this Coronavirus. Should that happen, it would be done by a recognized producer under license.
We are hopeful that the N-Assay and one additional Point-of Care test we are developing will be useful tools for rapid detection of any pathogens that are threats to health.
A recap of our late-February Update:
While we believe our technology could be used to develop a rapid test for the Coronavirus, based upon preliminary development work done for detection of proteins associated with Ebola in 2014 and 2015, with <3.5 hours results, we do not have the resources to independently pursue development of a Coronavirus rapid test.
The Coronavirus may be a short-lived phenomenon that is no longer an issue within a few months; there are other tests that exist that may deliver reliable results in a few hours or days, and while an N-Assay test could potentially deliver results in minutes, it may not be viewed as worthwhile in a cost/benefit analysis by various agencies or institutions.
In conclusion, we are fully committed to our current work producing filled Petri plates and development work on Urinary Tract and Yeast Infection rapid detection development utilizing a unique screening test and our N-Assay modified ELISA process.
Posted On: 02/28/2020 11:32:38 AM
Posted By: mitstevfel
Response to Coronavirus Queries both International and US
The Company continues to receive calls inquiring about Coronavirus (COVID-19) testing capabilities.
While we believe our technology could be used to develop a rapid test for the Coronavirus, based upon preliminary development work done for detection of proteins associated with Ebola in 2014, we do not have the resources to pursue development of a Coronavirus rapid test. There are a small number of BioSafety Level 4 labs in the US (4+/-) where development work on dangerous viruses can be done and their calendars are booked months to years in advance with daily costs that can run into tens of thousands of dollars. The Coronavirus may be a short-lived phenomenon that is no longer an issue within a few months; there are other tests that exist that may deliver reliable results in a few hours or a day, and while a test we develop may potentially deliver results in minutes, it may not be viewed as worthwhile in a cost:benefit analysis by various agencies or institutions.
In conclusion, we are fully committed to our current work on Urinary Tract and Yeast Infections rapid detection development utilizing a unique screening test and our N-Assay modified ELISA process.
Posted On: 01/31/2020 3:04:22 PM
Posted By: Eudius
Update:
NanoLogix Incorporated
Response to Coronavirus Questions From Shareholders
Given a number of queries from shareholders asking if our technology could be used for rapid detection of the current Coronavirus originating in Wuhan, China we felt the following response is necessary:
Based upon positive preliminary research performed in 2014 with the N-Assay on Ebola virus protein markers, we believe both the N-Assay and the new Screening test currently under development have the potential for use in rapid detection of the Coronavirus. That said, given our focus on refinement of both the Screening Test and N-Assay Rapid Diagnostic for Urinary Tract and other bacterial and yeast infections, our limited resources as a small biotechnology company, along with the demonstrated historical lack of interest from potential partners and funders during the Ebola outbreak, we currently have no intention of individually pursuing development for Coronavirus detection without the assistance and cooperation of well-funded entities.
Posted On: 01/14/2020 11:21:31 AM
Posted By: Eudius
NanoLogix PreTest Development Update
NanoLogix is pleased to provide an additional update on the
Screening/Pretest and its potential as a standalone test
An important aspect of the Bacteria and Yeast pretest revealed during Phase One development is the ability to detect and specifically identify Candida yeast infection in human fluids, with no cross-reactivity from other microorganisms. The importance of this is three-fold. The first aspect is that this Candida test is a FIVE-MINUTE TEST. The second is that it can be offered for consumer use in retail outlets, in addition to being used by clinicians for laboratories and medical offices. The third is that there is no other consumer test that specifically identifies Candida, and in doing so, we believe it will provide the ability for consumers to self-diagnose and treat a condition that affects a large percentage of the public.
The previous update from December is provided below for reference
The first phase of Proof of Concept/Principle development work in the UK by a company with Global operations began on October 1st and was completed the first week of December at a cost of roughly $100,000. This phase demonstrated very positive results for Point of Care screening for one specific Candida strain and to very promising results for two bacteria that constitute the primary threats present in Urinary Tract Infections (UTI).
This was a necessary first of four phases that will carry through to patient studies in Houston planned for 2020. The next phase of development will begin in March, after the manufacture and delivery of custom antibodies for the remaining bacteria and Candida.
This schedule will lead to marketing of both the N-Assay and its associated screening pretest for UTI projected for 2021.
The development work on a screening/pretest for seven bacteria and two strains of Candida, though initially focussed upon UTI, will enable NanoLogix to configure the test in a multitude of ways. In doing so, we will have the capability to rapidly and accurately test for possibly up to 15-20 different types of infections, with the ability to determine the specific bacterial cause, the severity of the infection, and the bacteria antibiotic resistance. We anticipate the tests will provide Point of Care and Clinical personnel the ability to dramatically increase both accuracy and speed of diagnosis and in doing so will provide a new weapon in the battle against the development of antibiotic resistance.
The purpose of the Pretest use with the N-Assay is to have a Pretest that will indicate the presence of a specific bacteria within minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required.
In our effort to secure additional funding to reach our goal of $3 million for development, expansion and marketing, we have been in contact with a number of non-NanoLogix-affiliated MDs who have expressed interest in the technology development. Those efforts will continue until we reach our funding requirements.
A PowerPoint presentation on the N-Assay Bacteria Diagnostic is included to illustrate just some of the advantages of the technology. The PowerPoint includes information on upper respiratory infections (URI), general sepsis infections, and sepsis infections related to infant low-birth weights. In future updates there will be information on shares of the diagnostic market devoted to each of those, and other infections for which configurations of the N-Assay are being explored.
Read More: https://investorshangout.com/Nanologix-Inc-NN...z6YBK76ng8
3
2
